Business Wire

CIRIUM

29.12.2020 08:02:09 CET | Business Wire | Press release

Share
21 Years of Airline Passenger Traffic Growth Wiped out in 2020: Cirium Report Reveals

Global aviation data firm Cirium today released its new Airline Insights Review 2020 which reveals the shocking impact on aviation of worldwide travel restrictions to curb COVID-19.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201228005254/en/

The report shows that the pandemic and its consequences wiped out 21 years of global passenger traffic growth in a matter of months, reducing traffic this year to levels last seen in 1999. In comparison to last year, passenger traffic is estimated to be down 67% in 2020.

At the peak of the disruption in April, scheduled passenger flights dropped significantly to just 13,600 globally on April 25, compared to the year’s busiest day on January 3 when Cirium tracked over 95,000 scheduled passenger flights globally. This marks an extraordinary 86% reduction in flights.

From January to December airlines operated 49% fewer flights in 2020 compared to 2019 – down from 33.2 million flights to just 16.8 million (to December 20).

Domestic travel was down 40% this year, from 21.5 million flights in 2019, while international flights suffered an even more precipitous drop as they were 68% below the 11.7 million flights tracked the year before.

Jeremy Bowen, CEO of Cirium, said: “This severe setback shows the true extent of the challenge faced by the struggling aviation sector as it has sought to reset itself in the new post COVID-19 era.”

“Whereas this time last year we were celebrating the on-time performance of global carriers, this year is dramatically different. Most global airlines were largely on time in 2020; it’s just a shame that the traveling public, airlines and aviation firms worldwide didn’t benefit.

“The factors which usually cause delay, such as congested airspace, taxiways and late connecting passengers simply did not exist in 2020.”

The Cirium Airline Insights Review 2020 replaces Cirium’s annual On-Time Performance Review which for more than a decade has identified the world’s best performing airlines and airports for on-time flight operations.

NEW AIRLINE INSIGHTS REVIEW: FLIGHTS FLOWN DRAMATICALLY DOWN

Global passenger traffic figures reveal a plunge of over two thirds (67%) versus the previous year, with Asia-Pacific continuing to handle over a third of world passenger traffic.

The majority of the scheduled passenger flights flown this year have been domestic – totaling 13 million (77%) with a mere 3.8 million (23%) flying internationally, due to closed borders and limited business travel.

Cirium data analysis recorded Southwest Airlines operating the most flights globally (and in North America), with 854,800 flights in total. Meanwhile, China Southern Airlines (487,700 flights) topped the tables in the Asia-Pacific, Ryanair in Europe (205,000 flights), Azul in Latin America (134,000 flights) and Qatar Airways (82,400 flights) in the Middle East and Africa.

On the ground, Atlanta was the world’s busiest airport, handling over 245,000 arriving flights during 2020, while the world’s busiest air route in both directions was within South Korea, between Seoul and the island of Jeju with 70,700 flights operated.

Forward planning for airlines has dramatically contracted from six- to 12-months for flight scheduling to just six- to eight-weeks – forcing carriers to be nimbler and adapt with greater speed to the rapidly changing rules and travel restrictions around the world.

FLEETS IN STORAGE (BUT NOT THE A320)

As airlines have been forced to drastically reduce the number of aircraft still in service, those still flying are operating significantly fewer hours.

For example, narrowbody aircraft operated just six to seven hours a day in Q3 2020 compared to nine to 10 hours a day in the same period last year.

While up to 30% of the global passenger fleet remains in storage there are signs of recovery on the horizon, with only 10% of short-haul Airbus A320neo aircraft currently in storage showing narrowbody aircraft leading the recovery and domestic and short-haul travel returning first.

With domestic and short-haul services ruling the day, the world’s most used aircraft type was the Airbus A320 with Cirium tracking 5.49 million flights throughout 2020.

SEVEN TRENDS IDENTIFIED BY CIRIUM

“Airlines will have a way before returning to 2019 levels particularly as international travel is significantly down and showing only slow signs of recovery, mainly China and Southeast Asia,” Jeremy Bowen added.

“But Cirium is confident aviation will weather this difficult and terrible year and emerge in better shape – with younger more fuel-efficient aircraft and right-sized fleets – to gradually navigate their way to recovery in the years ahead.”

The seven key trends outlined by The Cirium Airline Insights Review 2020 for next year include:

  1. The consolidation of airlines , particularly in Asia-Pacific where more domestic competitors will merge or be acquired.
  2. New-generation aircraft like the A320neo and the return of the 737 Max, will provide reduced operating costs.
  3. Surplus aircraft will be retired and the Boeing 747 and the Airbus A380 are projected to support the rising demand in the denser leisure markets.
  4. In Q4 we saw a 78% plunge in bookings compared to the same period last year – this will naturally change the way the industry forecasts demand , we are seeing on-line search and sentiment becoming the primary indicators to calculate demand.
  5. Airlines will need to deploy more dynamic scheduling with the increased volatility of flight scheduling, as the booking window has fallen from six- to 12-months to just six- to eight-weeks.
  6. The implementation of AI technology will accelerate to automate the traveler experience and real-time proactive information will become more critical.
  7. Aircraft leasing will push past 50% becoming the major manner in which aircraft are financed .

To read the full Cirium Airline Insights Review 2020 – click here.

Bowen thanked the OTP board members comprised of Henry Harteveldt at Atmosphere Research group and Dr. Mario Hardy at Pacific Asia Travel Association (PATA) for their insights and contributions to the Airline Insight Review 2020.

For further information please visit www.cirium.com and follow Cirium updates via LinkedIn and Twitter .

About Cirium
Cirium brings together powerful data and analytics to keep the world moving. Delivering insight, built from decades of experience in the sector, enabling travel companies, aircraft manufacturers, airports, airlines and financial institutions, among others, to make logical and informed decisions which shape the future of travel, growing revenues and enhancing customer experiences. Cirium is part of RELX, a global provider of information-based analytics and decision tools for professional and business customers.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release

For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye